Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. (15th October 2018)

• Record Type: Journal Article
• Authors: Wang, Hao; Zeng, Chenxin; Li, Xin; Wang, Youjie; Li, Xinyi; Ge, Weihong
• Is Part Of: Future oncology. Volume 15:Number 2(2019)
• Page Start: 181
• Page End: 191
• Publication Date: 2018-10-15
• Subjects: afatinib -- China -- cost utility -- EGFR-mutated -- non-small-cell lung cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0692
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR -mutated non-small-cell lung cancer treatments from the Chinese healthcare system perspective.Materials & methods: A Markov model was established, state transition probabilities were extracted from the LUX-Lung7 trial and utility values were from previous studies. The cost was extracted from local charge or relevant literature. Incremental cost–effectiveness ratio was calculated for intention-to-treat, EGFR exon 19 deletion (del19) and exon Leu858Arg (21L858R, L858R) muation subgroups. Results: For the entire population, the afatinib regimen afforded additional 0.29 quality-adjusted life years (QALYs). Incremental cost–effectiveness ratios were US$9820.41/QALY, US$18, 529.65/QALY and US$1585.51/QALY for intention-to-treat, L858R and del19, respectively.Conclusion: First-line afatinib was more cost–effective than gefitinib for EFGR-mutated advanced non-small-cell lung cancer in China.